Base Year
Historical Year
Forecast Year
The North America gastric cancer drugs market is expected to grow at a CAGR of 17.10% during the forecast period of 2024-2032, driven by the increased regulatory approval of novel therapies and the growing emphasis on oncology research.
Gastric cancer is reported to be one of the most life-threatening diseases due to the absence of effective medications and delayed diagnosis. The commonly used treatments include chemotherapy, radiation therapy, and targeted therapy. The stage of gastric cancer and the presence of specific biomarkers usually determine the treatment plan. Recent years have witnessed pivotal progress in the development of novel therapies which is likely to shape the global gastric cancer drugs market dynamics. Medications such as imatinib, regorafenib, entrectinib, and Larotrectinib are increasingly used to treat advanced gastric cancer. Moreover, the surge in clinical trial activities stimulated by substantial fundings in oncology research is poised to propel the North America gastric cancer drugs market growth.
Gastric cancer is a significant health challenge in North America. In 2023, stomach cancer was estimated to cause around 11,130 deaths in the United States. Metastatic gastric cancer is reported to have the lowest 5-year survival rate at 7%. The most frequently diagnosed demographic is individuals between the ages of 65 to 74 years, indicating the need for early detection and successful therapies. Thus, the rising incidence of gastric cancer risk factors (such as aging and sedentary lifestyles) coupled with the increased patient awareness and screening of the disease is projected to fuel the North America gastric cancer drugs market demand in the forecast period.
One of the major market trends is the increased approval of potent gastric cancer drugs by health regulatory bodies. In November 2023 , Merck & Co., Inc.’s immune checkpoint inhibitor pembrolizumab (Keytruda) with fluoropyrimidine- and platinum-containing chemotherapy received United States Food and Drug Administration (FDA) approval for the first-line treatment for gastric or gastroesophageal junction (GEJ) adenocarcinoma in adult patients. The phase 3 KEYNOTE-859 trial of the drug candidate revealed that administration of pembrolizumab before chemotherapy in HER2-negative advanced gastric or GEJ adenocarcinoma patients resulted in significant improvement in overall survival and progression-free survival (PFS), which prompted the FDA approval. The introduction of such innovative drugs to treat gastric cancer is anticipated to elevate the market value in the coming years.
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Therapy Type | Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery, Others |
| Disease Type | Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Others |
| Drug Class | PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others |
| Route of Administration | Oral, Injectable |
| End Use | Ambulatory Surgery Centers, Hospitals and Specialty Clinics, Others |
| Distribution Channel | Hospital Pharmacies, Specialty and Retail Pharmacies, Others |
| Countries | United States of America, Canada |
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Novartis AG
Novartis AG, a Swiss multinational pharmaceutical company, leverages innovative science and digital technologies to develop transformative treatments in areas of unmet medical needs including gastric cancer therapies.
Pfizer, Inc.
This leading research-based pharmaceutical and biomedical company is actively investing in the creation of novel oncology treatments. Its drug candidate for gastric cancer, PF-08046054 , is currently under clinical development.
Viatris, Inc.
Viatris Inc., an American global pharmaceutical and healthcare company, produces high-quality medicines across a range of therapeutic categories. It offers branded, generics, biosimilars, and over-the-counter pharmaceutical products including the first-ever FDA-approved biosimilar OGIVRI (trastuzumab) for metastatic gastric cancers.
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd., a leading healthcare company operates globally under two divisions, namely, pharmaceuticals and diagnostics. Its drug candidate Atezolizumab is under clinical development for the treatment of gastric cancer.
Other players in the market include Eli Lilly and Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, Celltrion Healthcare Co., Ltd., and Samsung Biologics Co., Ltd.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapy Type |
|
| Breakup by Disease Type |
|
| Breakup by Drug Class |
|
| Breakup by Route 0f Administration |
|
| Breakup by End Use |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
North America Gastric Cancer Drugs Market Size
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is anticipated to grow at a CAGR of 17.10% during the forecast period of 2024-2032, driven by increasing emphasis on oncology research in the region.
The rising incidence of gastric cancer risk factors and heightened patient awareness are fuelling the demand for the market.
One of the significant trends in the market is surge in approvals for novel gastric cancer drugs by health regulatory bodies. In November 2023 , Merck & Co., Inc.’s immune checkpoint inhibitor pembrolizumab (Keytruda) with chemotherapy received FDA approval to treat gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Based on the therapy type, the market is segmented into chemotherapy, targeted therapy, immunotherapy, radiation therapy, and surgery, among others.
By disease type, the market is divided into adenocarcinoma, lymphoma, gastrointestinal stromal tumor, and carcinoid tumor, among others.
By drug class, the market is divided into PD-1/PD-L1 inhibitors, HER2 antagonists, and VEGFR2 antagonists, among others.
The market breakup by route of administration includes oral and injectable.
Market breakup by end-use includes ambulatory surgery centers, hospitals, and specialty clinics, among others.
Major distribution channels of the market include hospital pharmacies, specialty, and retail pharmacies, among others.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are Novartis AG, Pfizer, Inc., Viatris, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, Celltrion Healthcare Co., Ltd., and Samsung Biologics Co., Ltd.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share